<DOC>
	<DOCNO>NCT00981695</DOCNO>
	<brief_summary>Objectives : Primary : Safety immunogenicity MVA.HIVA vaccine 20-week-old healthy Kenyan infant born HIV-1-infected mother . Secondary : - HIV-1 immunogenicity comparison MVA.HIVA age-matched unvaccinated control arm cohort ( breastfeed formula feed ) - HIV-1 immunogenicity comparison breastfeed formula feed infant receive MVA.HIVA - HIV-1 immunogenicity comparison breastfeed formula feed infant age-matched unvaccinated control group - Comparison responses certain Kenyan Extended Programme Immunization ( KEPI ) vaccine ( OPV , DTP , HBV , HiB ) MVA.HIVA versus age-matched unvaccinated control cohort , breast versus formula feed infant age-matched unvaccinated control group , breast versus formula infant receive MVA.HIVA - Comparison immune activation phenotypic profile lymphocytes breast formula feed infant cohort ( MVA.HIVA age-matched unvaccinated control ) - Build capacity Infant HIV-1 Vaccine Clinical Trials Centre Nairobi , Kenya .</brief_summary>
	<brief_title>Safety Immunogenicity Study Candidate HIV-1 Vaccine Given Healthy Infants Born HIV-1-infected Mothers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infant Inclusion Criteria Healthy infant &lt; 3 day age ( day birth = Day 0 ) enrolment Birth weight &gt; 2500 gram Born eligible woman Written inform consent parent Infant Exclusion Criteria HIV infection , determine filter paper and/or RNA test prior vaccination . Participation HIV1 vaccine drug trial . Failure receive standard KEPI immunization accord national immunization programme . Weight age zscores outside 2 standard deviation normal time vaccination . Acute disease time vaccination ( acute disease define presence moderate severe illness without fever ) . All vaccine administer person minor illness diarrhoea , mild upper respiratory tract infection without lowgrade febrile illness , i.e. , temperature &lt; 37.5 °C ) . Axillary temperature ≥ 37.5 °C time vaccination . Any clinically significant abnormal find screen biochemistry haematology time vaccination . History allergic disease reaction likely exacerbate component vaccine , e.g. , egg product . Presence underlying disease compromise diagnosis evaluation response vaccine . Any ongoing chronic illness require hospital specialist supervision . Administration immunoglobulins and/or blood product within one month precede plan administration vaccine candidate . Any history anaphylaxis reaction vaccination . Research Physician 's assessment lack willingness parent participate comply requirement protocol , identification factor felt significantly increase infant 's risk suffer adverse outcome . Likelihood travel away study area .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Days</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>MVA</keyword>
	<keyword>PMTCT</keyword>
	<keyword>HIV preventive vaccine</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>